Karolinska Development Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Viktor Drvota

Chief Executive Officer (CEO)

kr4.7m

Compensación total

Porcentaje del salario del CEO	62.9%
Permanencia del CEO	7yrs
Participación del CEO	0.08%
Permanencia media de la dirección	4yrs
Promedio de permanencia en la Junta Directiva	3.3yrs

Actualizaciones recientes de la dirección

Recent updates

We Think That There Are Some Issues For Karolinska Development (STO:KDEV) Beyond Its Promising Earnings

May 04

Is Karolinska Development (STO:KDEV) Using Too Much Debt?

Aug 19

Karolinska Development AB (publ)'s (STO:KDEV) CEO Might Not Expect Shareholders To Be So Generous This Year

Apr 27

We're Not So Sure You Should Rely on Karolinska Development's (STO:KDEV) Statutory Earnings

Feb 08

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Viktor Drvota en comparación con los beneficios de Karolinska Development?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	kr34m
Dec 31 2023	kr5m	kr3m	kr5m
Sep 30 2023	n/a	n/a	kr17m
Jun 30 2023	n/a	n/a	-kr41m
Mar 31 2023	n/a	n/a	-kr87m
Dec 31 2022	kr6m	kr3m	-kr88m
Sep 30 2022	n/a	n/a	-kr118m
Jun 30 2022	n/a	n/a	-kr72m
Mar 31 2022	n/a	n/a	kr166m
Dec 31 2021	kr5m	kr3m	kr171m
Sep 30 2021	n/a	n/a	kr276m
Jun 30 2021	n/a	n/a	kr108m
Mar 31 2021	n/a	n/a	-kr106m
Dec 31 2020	kr5m	kr3m	-kr207m
Sep 30 2020	n/a	n/a	kr35m
Jun 30 2020	n/a	n/a	kr190m
Mar 31 2020	n/a	n/a	kr195m
Dec 31 2019	kr6m	kr3m	kr303m
Sep 30 2019	n/a	n/a	-kr11m
Jun 30 2019	n/a	n/a	kr8m
Mar 31 2019	n/a	n/a	kr32m
Dec 31 2018	kr5m	kr3m	kr31m
Sep 30 2018	n/a	n/a	kr48m
Jun 30 2018	n/a	n/a	kr238m
Mar 31 2018	n/a	n/a	kr185m
Dec 31 2017	kr5m	kr1m	kr180m

Compensación vs. Mercado: La compensación total de Viktor($USD450.13K) está por encima de la media de empresas de tamaño similar en el mercado Swedish ($USD257.03K).

Compensación vs. Ingresos: La compensación de Viktor ha sido consistente con los resultados de la empresa en el último año.

CEO

Viktor Drvota (59 yo)

7yrs

Permanencia

kr4,733,000

Compensación

Dr. Viktor Drvota, M.D., Ph D., has been an Independent Director of OssDsign AB since 2015. He serves as Chairman of the Board at Modus Therapeutics Holding Ab since 2016.He serves as the Chief Executive...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Viktor Drvota	Chief Executive Officer	7yrs	kr4.73m	0.078% SEK 311.2k
Hans Toll	Chief Financial Officer	1.7yrs	sin datos	0.013% SEK 51.9k
Per Aniansson	Investment Director	3.3yrs	sin datos	0.059% SEK 237.1k
Eva Montgomerie	Head of Accounting	10.7yrs	sin datos	0.012% SEK 49.0k
John Öhd	Chief Scientific Officer & Venture Partner	4yrs	sin datos	sin datos
Johan Dighed	Chief Legal Officer & Deputy CEO	4.1yrs	sin datos	0.15% SEK 593.1k
Yan Cheng	President of Asia	6.9yrs	sin datos	0.0093% SEK 37.1k
Tse Ping	Senior Strategic Advisor	no data	sin datos	sin datos
Linda Spahiu	Investment Manager	no data	sin datos	0.0037% SEK 14.8k
Mikaela Sörman	Investment Manager	no data	sin datos	0.0037% SEK 14.8k

4.0yrs

Permanencia media

54.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de KDEV se considera experimentado (4 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Hans Wigzell	Chairman	less than a year	kr500.00k	sin datos
Anna Lefevre Skjoldebrand	Independent Director	3.3yrs	kr200.00k	sin datos
Y. Y. Tse	Director	7.4yrs	sin datos	sin datos
Ben Toogood	Director	3.3yrs	kr178.00k	0.024% SEK 94.9k
Philip Duong	Director	2.4yrs	kr200.00k	sin datos

3.3yrs

Permanencia media

48yo

Promedio de edad

Junta con experiencia: La junta directiva de KDEV se considera experimentada (3.3 años de antigüedad promedio).

Karolinska Development Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Karolinska Development AB (Publ) Announces That Björn Cochlovius Has Declined Re-Election

Chief Executive Officer recently bought kr81k worth of stock

Chief Legal Officer & Deputy CEO recently bought kr165k worth of stock

Chief Legal Officer & Deputy CEO recently bought kr56k worth of stock

Chief Legal Officer & Deputy CEO recently bought kr89k worth of stock

Chief Legal Officer & Deputy CEO recently bought kr84k worth of stock

Recent updates

Karolinska Development AB (publ) to Report Fiscal Year 2024 Final Results on Mar 21, 2025

We Think That There Are Some Issues For Karolinska Development (STO:KDEV) Beyond Its Promising Earnings

First quarter 2024 earnings released

Karolinska Development AB (Publ) Announces That Björn Cochlovius Has Declined Re-Election

Full year 2023 earnings released: EPS: kr0.02 (vs kr0.34 loss in FY 2022)

New major risk - Revenue and earnings growth

Chief Executive Officer recently bought kr81k worth of stock

Full year 2023 earnings released: EPS: kr0.02 (vs kr0.34 loss in FY 2022)

Karolinska Development AB (publ) to Report First Half, 2024 Results on Aug 30, 2024

Third quarter 2023 earnings released: EPS: kr0.044 (vs kr0.17 loss in 3Q 2022)

Karolinska Development AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 40.3 million.

Ossdsign Receives FDA Clearance for the Use of OssDsign Catalyst in Interbody Cages in Spinal Surgery

Second quarter 2023 earnings released: EPS: kr0.086 (vs kr0.083 loss in 2Q 2022)

Chief Legal Officer & Deputy CEO recently bought kr165k worth of stock

Chief Legal Officer & Deputy CEO recently bought kr56k worth of stock

Chief Legal Officer & Deputy CEO recently bought kr89k worth of stock

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings released: kr3.43 loss per share (vs kr0.97 profit in FY 2021)

Karolinska Development AB (Publ) Announces That Its Portfolio Company Dilafor’S Extended Clinical Phase 2B Study with the Drug Candidate Tafoxiparin Has Resulted in Further Positive Data

Chief Legal Officer & Deputy CEO recently bought kr84k worth of stock

Third quarter 2022 earnings released

Karolinska Development AB (publ) to Report First Half, 2023 Results on Aug 25, 2023

Karolinska Development AB (publ), Annual General Meeting, May 16, 2023

Price target decreased to kr5.40

Less than half of directors are independent

Modus Therapeutics AB's Portfolio Company Modus Therapeutics Completes Recruitment in a Clinical Phase 1B Study of Sevuparin

Karolinska Development AB Announces Chief Financial Officer Changes

Karolinska Development’s portfolio company Modus Therapeutics initiates inclusion in phase 1 study of sevuparin in pediatric patients with severe malaria

Second quarter 2022 earnings released

Karolinska Development's Portfolio Company Initiated A Clinical Phase 1 Program with PN-6047

Karolinska Development AB (publ) to Report Fiscal Year 2022 Results on Feb 17, 2023

Investor sentiment improved over the past week

First quarter 2022 earnings released

Price target increased to kr7.90

Less than half of directors are independent

Karolinska Development AB (Publ) Announces Portfolio Company Ossdsign Completes Patient Enrolment to the Top Fusion Study

Full year 2021 earnings released: EPS: kr0.97 (vs kr1.18 loss in FY 2020)

Investor sentiment deteriorated over the past week

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Karolinska Development AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 377.64874 million.

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Organon & Co. (NYSE:OGN) completed the acquisition of Forendo Pharma Ltd from Karolinska Development AB (publ) (OM:KDEV), KD Co-Investment Fund KB, fund managed by Karolinska Development AB (publ) and others.

Karolinska Development’s Portfolio Company Modus Therapeutics Initiates Phase 1b Trial of Its Drug Candidate Sevuparin

Third quarter 2021 earnings released

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: EPS kr1.23 (vs kr0.012 in 2Q 2020)

Is Karolinska Development (STO:KDEV) Using Too Much Debt?

Karolinska Development AB Announces the US Food and Drug Administration Issued A Clinical Hold for Aprea Therapeutics Clinical Program

Karolinska Development AB (publ) (OM:KDEV) acquired additional 21% minority stake in Anacardio AB.

First quarter 2021 earnings released

Karolinska Development AB (publ)'s (STO:KDEV) CEO Might Not Expect Shareholders To Be So Generous This Year

Full year 2020 earnings released: kr1.18 loss per share (vs kr4.10 profit in FY 2019)

CFO & Deputy CEO Fredrik Jarrsten has left the company

Karolinska Development AB Announces CFO Changes

Karolinska Development Appoints Johan Dighed as Deputy CEO

New 90-day low: kr1.59

Karolinska Development AB (publ) Announces Management Appointments

Full year 2020 earnings released: kr1.18 loss per share (vs kr4.10 profit in FY 2019)

New 90-day low: kr1.61

We're Not So Sure You Should Rely on Karolinska Development's (STO:KDEV) Statutory Earnings

New 90-day low: kr1.80

Investor sentiment deteriorated over the past week

New 90-day low: kr2.17

New 90-day low: kr2.31

New 90-day low: kr2.60

New 90-day low: kr2.61